SCHEMBL2597852

SCHEMBL2597852

CC(C)(C)OC(=O)N1CC(CO)OCC1CCc1ccccc1

nearest known ligand 0.41

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
KLK7 P49862 1/20 0.41
NR1H2 P55055 3/20 0.39
NR1H3 Q13133 2/20 0.39
SRC P12931 4/20 0.39
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
CYP3A4 P08684 1/20 0.37
PARP1 P09874 1/20 0.37
GAA P10253 1/20 0.37
THRB P10828 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
PTPN1 P18031 1/20 0.37
JAK2 O60674 1/20 0.37
JAK1 P23458 1/20 0.37
TACR1 P25103 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2597809 0.88 KLK7 (0.42) KLK7NR1H2NR1H3CYP3A4PARP1
SCHEMBL2597820 0.86 KLK7 (0.41) KLK7NR1H2NR1H3GAATHRB
SCHEMBL14736583 0.84 DRD4 (0.39)
SCHEMBL26707816 0.79 CYP3A4 (0.40) NR1H2NR1H3MEN1KMT2ACYP3A4
SCHEMBL3237401 0.79 NR1H2 (0.43) KLK7NR1H2NR1H3MEN1KMT2A
SCHEMBL1318992 0.79 NR1H2 (0.40) NR1H2SRCMEN1KMT2ACYP3A4
SCHEMBL14636816 0.79 SRC (0.38) KLK7NR1H2NR1H3SRCMEN1
SCHEMBL17895054 0.79 SRC (0.38) KLK7NR1H2NR1H3SRCMEN1
SCHEMBL31410012 0.79 SRC (0.38) KLK7NR1H2NR1H3SRCMEN1
SCHEMBL14636814 0.79 SRC (0.38) KLK7NR1H2NR1H3SRCMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2571359-A1 NOVEL PROLYLCARBOXYPEPTIDASE INHIBITORS Merck Sharp & Dohme Corp. (US) 2013-03-27 EP disclosed
US-20130059830-A1 NOVEL PROLYLCARBOXYPEPTIDASE INHIBITORS MERCK SHARP & DOHME CORP 2013-03-07 US disclosed
US-20130059830-A1 NOVEL PROLYLCARBOXYPEPTIDASE INHIBITORS MERCK SHARP & DOHME CORP 2013-03-07 US disclosed
US-20130059830-A1 NOVEL PROLYLCARBOXYPEPTIDASE INHIBITORS MERCK SHARP & DOHME CORP 2013-03-07 US disclosed
WO-2011146354-A1 NOVEL PROLYLCARBOXYPEPTIDASE INHIBITORS MERCK SHARP & DOHME CORP. (US) 2011-11-24 WO disclosed
WO-2011146354-A1 NOVEL PROLYLCARBOXYPEPTIDASE INHIBITORS MERCK SHARP & DOHME CORP. (US) 2011-11-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130059830-A1 NOVEL PROLYLCARBOXYPEPTIDASE INHIBITORS PRCP, PREP, ENPEP KLK7 2012/4885NR1H2 2668/4885NR1H3 2970/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.